IHS Chemical Week

EnviroTech :: R&D

Wacker Signs Licensing Deal with Xoma

4:28 PM MDT | June 23, 2008 | Deepti Ramesh

Wacker Biotech (Jena, Germany), a subsidiary of Wacker Chemie, says it has signed a licensing agreement with biopharmaceutical company Xoma (Berkeley, CA), to use Xoma’s bacterial cell expression technology for R&D. The agreement allows Wacker Biotech to combine its proprietary E. coli secretion technology with Xoma’s bacterial cell expression technology to produce antibodies and antibody fragments, Wacker Biotech says. Xoma will use Wacker Biotech’s E. coli secretion technology for a development project to produce an antibody fragment...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa